臨床初步篩查功能
Massive Bio 獲選為 OpenAI 腫瘤學 AI 精選合作夥伴
Massive Bio 獲選為 OpenAI Partner Network 旗下的 OpenAI Select Partner，擴大其運用人工智能進行腫瘤學臨床試驗配對及臨床研究工作流程的業務。這項認證，讓 Massive Bio 在 OpenAI 的合作夥伴生態系統中，取得正式角色，協助其為醫療系統、研究網絡、生物製藥公司及病人支援機構擴展人工智能工具的應用。
Massive Bio 的平台運用人工智能，將複雜的臨床試驗資格準則，轉化為結構化、可供機器讀取的參數，並結合臨床及生物標記數據，為病人識別潛在的試驗選項。公司計劃在投資人才培訓的同時，擴大其與 OpenAI 相關的產品服務，而人手監督及成效評估仍是其部署方式的一部分。
對臨床醫生及病人而言，這項合作有望加快臨床試驗的識別過程，並減少人手篩查的工作量。這亦反映生成式人工智能，正日益被運用於簡化複雜的腫瘤學研究及病人取用醫療資源的流程。
英文原文
Massive Bio was named an OpenAI Select Partner within the OpenAI Partner Network, expanding its work using AI for oncology clinical trial matching and clinical research workflows. The designation gives Massive Bio a formal role within OpenAI’s partner ecosystem as it scales AI tools for health systems, research networks, biopharmaceutical companies and patient-support organizations.
Massive Bio’s platform uses AI to convert complex clinical trial eligibility criteria into structured, machine-readable parameters and combines clinical and biomarker data to identify potential trial options for patients. The company plans to expand its OpenAI-related offerings while investing in talent and training, with human oversight and performance evaluation remaining part of its deployment approach.
For clinicians and patients, the partnership could support faster trial identification and reduce manual screening work. It also reflects growing use of generative AI to streamline complex oncology research and patient-access workflows.
- 來源
- Trend Hunter
- 發布
- 2026-08-14
- 品類
- Ai
- 出處
- mobihealthnews, businesswire